ArticleCancer cell international2026
Dysregulation of ferroptosis-related genes and the ACSL4-mediated ferroptosis-PD-L1 axis in prostate cancer pathogenesis.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prostate cancer (PCa) is a major cause of morbidity and mortality worldwide. Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a crucial mechanism in various cancers, including PCa. This study focused on two interrelated aspects of ferroptosis in PCa. Firstly, it sought to determine whether ferroptosis-related genes are dysregulated in PCa and correlate with disease subtypes and prognosis. Secondly, it aimed to investigate whether the ACSL4/PD-L1 axis mediates crosstalk between ferroptosis and the immune microenvironment. Using TCGA data, we identified 1019 differentially expressed genes (DEGs) between PCa and normal tissues, with the ferroptosis pathway prominently highlighted. Key ferroptosis genes exhibited altered expression profiles in PCa, suggesting their involvement in PCa pathogenesis. By constructing correlation networks, we revealed coordinated regulatory interactions between these genes in PCa. To better understand the implications of ferroptosis in PCa, we performed subtype analysis of PCa patients based on ferroptosis gene expression, identifying two stable subtypes. Lasso-Cox regression analysis further stratified patients into high and low-risk groups, which exhibited significant prognostic differences. Additionally, we explored the relationship between PD-L1, ferroptosis, and the immune microenvironment. PD-L1 expression was significantly lower in PCa tissues compared to normal tissues and varied across subtypes. It correlated strongly with ferroptosis-related genes ACSL4 and TFRC. Single-cell RNA sequencing revealed ACSL4 is predominantly expressed in fibroblasts within the PCa tumor microenvironment. Functional assays confirmed that ACSL4 positively regulated PD-L1 and that ferroptosis inhibition abrogates this regulatory effect. These findings highlight the complex interplay between ferroptosis, immune modulation, and prognosis in PCa, providing insights into potential therapeutic strategies that target ferroptosis-related pathways and immune checkpoint regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.